Correction to: The effect of the peritoneal tumor microenvironment on invasion of peritoneal metastases of high-grade serous ovarian cancer and the impact of neoadjuvant chemotherapy

Autor: C. A. R. Lok, Hugo M. Horlings, F. C. Amant, K. K. van de Vijver, E. S. Jordanova, W.J. van Driel, J. O.A.M. van Baal

Publikováno v: Virchows Archiv. 478:611-611

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::ba0b5a82cc68ef6933312deafff20d72
https://doi.org/10.1007/s00428-020-02974-7

Paired-box gene 2 is down-regulated in endometriosis and correlates with low epidermal growth factor receptor expression

Autor: Cleophas M. Kyama, K K Van de Vijver, A.A. de Graaff, Andrea Romano, B. Delvoux, Thomas D'Hooghe, Gerard A.J. Dunselman

Publikováno v: Human Reproduction, 27(6), 1676-1684. Oxford University Press

background: Paired-box 2 (Pax2) is involved in the development of the female genital tract and has been associated with endometrial pathologies. The expression of Pax2 is induced by epidermal growth factor (EGF) and estrogens. In the present study, P

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::22c7a595cc8c1950c420a4cc3e63296e
https://doi.org/10.1093/humrep/des124

Unleashing NK- and CD8 T cells by combining monalizumab and trastuzumab for metastatic HER2-positive breast cancer: Results of the MIMOSA trial.

Autor: Geurts VCM; Division of Tumor Biology & Immunology, Netherlands Cancer Institute, Amsterdam, the Netherlands., Voorwerk L; Division of Tumor Biology & Immunology, Netherlands Cancer Institute, Amsterdam, the Netherlands., Balduzzi S; Department of Biometrics, Netherlands Cancer Institute, Amsterdam, the Netherlands., Salgado R; Department of Pathology, ZAS, Antwerp, Belgium; Division of Research, Peter Mac Callum Cancer Center, Melbourne, Victoria, Australia., Van de Vijver K; Department of Pathology, University Hospital Ghent, Cancer Research Institute Ghent (CRIG), Ghent, Belgium., van Dongen MGJ; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands., Kemper I; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands., Mandjes IAM; Department of Biometrics, Netherlands Cancer Institute, Amsterdam, the Netherlands., Heuver M; Department of Biometrics, Netherlands Cancer Institute, Amsterdam, the Netherlands., Sparreboom W; Astra Zeneca, The Hague, the Netherlands., Haanen JBAG; Division of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, the Netherlands., Sonke GS; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands., Horlings HM; Department of Pathology, Netherlands Cancer Institute, Amsterdam, the Netherlands., Kok M; Division of Tumor Biology & Immunology, Netherlands Cancer Institute, Amsterdam, the Netherlands; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands. Electronic address: M.Kok@nki.nl.

Publikováno v: Breast (Edinburgh, Scotland) [Breast] 2023 Aug; Vol. 70, pp. 76-81. Date of Electronic Publication: 2023 Jun 27.

Homologous recombination repair deficiency (HRD) testing in newly diagnosed advanced-stage epithelial ovarian cancer: A Belgian expert opinion.

Autor: Vergote I, Denys H, Altintas S, Kerger J, Baurain JF, Bours V, Henry S, Van de Vijver K, Lambrechts D, Gennigens C

Publikováno v: Facts, views & vision in ObGyn [Facts Views Vis Obgyn] 2022 Jun; Vol. 14 (2), pp. 111-120.

Immunohistochemical biomarkers are prognostic relevant in addition to the ESMO-ESGO-ESTRO risk classification in endometrial cancer.

Autor: Vrede SW; Department of Obstetrics and Gynaecology, Radboud university medical center, Nijmegen, the Netherlands; Department of Obstetrics and Gynaecology, Canisius-Wilhelmina Hospital, Nijmegen, the Netherlands. Electronic address: stephanie.vrede@radboudumc.nl., van Weelden WJ; Department of Obstetrics and Gynaecology, Radboud university medical center, Nijmegen, the Netherlands., Visser NCM; Department of Pathology, Stichting PAMM, Eindhoven, the Netherlands; Department of Pathology, Radboud university medical center, Nijmegen, the Netherlands., Bulten J; Department of Pathology, Radboud university medical center, Nijmegen, the Netherlands., van der Putten LJM; Department of Obstetrics and Gynaecology, Radboud university medical center, Nijmegen, the Netherlands., van de Vijver K; Department of Pathology, Ghent University Hospital, Cancer Research Institute Ghent (CRIG), Ghent, Belgium., Santacana M; Department of Pathology and Molecular Genetics and Research Laboratory, Hospital Universitari Arnau de Vilanova, University of Lleida, IRBLleida, CIBERONC, Lleida, Spain., Colas E; Biomedical Research Group in Gynaecology, Vall Hebron Institute of Research, Universitat Autònoma de Barcelona, CIBERONC, Barcelona, Spain., Gil-Moreno A; Gynecological Department, Vall Hebron University Hospital, CIBERONC, Barcelona, Spain; Pathology Department, Vall Hebron University Hospital, CIBERONC, Barcelona, Spain., Moiola CP; Biomedical Research Group in Gynaecology, Vall Hebron Institute of Research, Universitat Autònoma de Barcelona, CIBERONC, Barcelona, Spain., Mancebo G; Department of Obstetrics and Gynaecology, Hospital del Mar, PSMAR, Barcelona, Spain., Krakstad C; Department of Obstetrics and Gynaecology, Haukeland University Hospital, Bergen, Norway; Centre for Cancer Biomarkers, Department of Clinical Science, University of Bergen, Bergen, Norway., Trovik J; Department of Obstetrics and Gynaecology, Haukeland University Hospital, Bergen, Norway., Haldorsen IS; Centre for Cancer Biomarkers, Department of Clinical Science, University of Bergen, Bergen, Norway; Mohn Medical Imaging and Visualization Centre, Department of Radiology, Haukeland University Hospital, Bergen, Norway., Huvila J; Department of Pathology, University of Turku, Turku, Finland., Koskas M; Department of Obstetrics and Gynaecology Department, Bichat-Claude Bernard Hospital, Paris, France., Weinberger V; Department of Obstetrics and Gynaecology, University Hospital in Brno and Masaryk University, Brno, Czech Republic., Bednarikova M; Department of Internal Medicine, Hematology and Oncology, University Hospital in Brno and Masaryk University, Brno, Czech Republic., Hausnerova J; Department of Pathology, University Hospital in Brno and Masaryk University, Brno, Czech Republic., van der Wurff AA; Department of Pathology, Elisabeth-TweeSteden Hospital, Tilburg, the Netherlands., Matias-Guiu X; Department of Pathology and Molecular Genetics and Research Laboratory, Hospital Universitari Arnau de Vilanova, University of Lleida, IRBLleida, CIBERONC, Lleida, Spain., Amant F; Department of Oncology, KU Leuven, Leuven, Belgium; Department of Gynaecologic Oncology, Netherlands Cancer Institute and Amsterdam Medical Centers, Amsterdam, the Netherlands., Snijders MPLM; Department of Obstetrics and Gynaecology, Canisius-Wilhelmina Hospital, Nijmegen, the Netherlands., Küsters-Vandevelde HVN; Department of Pathology, Canisius-Wilhelmina Hospital, Nijmegen, the Netherlands., Reijnen C; Department of Radiation Oncology, Radboud university medical center, Nijmegen, the Netherlands., Pijnenborg JMA; Department of Obstetrics and Gynaecology, Radboud university medical center, Nijmegen, the Netherlands.

Publikováno v: Gynecologic oncology [Gynecol Oncol] 2021 Jun; Vol. 161 (3), pp. 787-794. Date of Electronic Publication: 2021 Apr 12.